trending Market Intelligence /marketintelligence/en/news-insights/trending/GbggJOab50S7e90qEqx2eg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Pfizer recalling 2 lots of migraine drug for potential contamination

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Pfizer recalling 2 lots of migraine drug for potential contamination

Pfizer Inc. is voluntarily recalling two lots of its migraine drug Relpax due to possible microbiological contamination.

Relpax, or eletriptan hydrobromide, is approved by the U.S. Food and Drug Administration to treat acute migraine with or without aura in adults.

The lots were recalled as they may not meet the New York-based pharmaceutical giant's in-house microbiological specification for the potential presence of the bacteria Genus Pseudomonas and Burkholderia. The recall covers Relpax 40-milligram tablets that were distributed in the U.S. and Puerto Rico between June and July.

Products contaminated with microorganisms put patients at risk of having bacteria spread from the gut to the bloodstream, which might result in serious, life-threatening infections, as well as temporary gastrointestinal distress without serious infection, according to an Aug. 15 recall notification issued by the FDA.

The FDA noted that these risks are low for the general population but could potentially cause serious adverse events including life-threatening infections for certain vulnerable patient populations, such as patients with compromised immune systems, cystic fibrosis and chronic granulomatous disease.

Pfizer has not yet received any customer complaints or reports of adverse events related to Relpax.